Sign in

    Swapnil Malekar

    Research Analyst at Piper Sandler

    Swapnil Malekar, PhD, MBA, served as Vice President of Biotech Equity Research at Piper Sandler, specializing in biotechnology sector analysis with a focus on gene therapy and pharmaceutical innovation. During his tenure, he covered companies such as REGENXBIO and Immuneering, delivering coverage on four stocks overall, although his performance metrics indicate a 9% success rate and an average return of -45% per rating, with his single most profitable rating being a 37.3% gain on IMRX between July 2022 and July 2023. Malekar joined Piper Sandler in June 2021 following previous analyst roles at Barclays and Jefferies and scientific positions at Novartis and Teva Pharmaceuticals, before moving to AstraZeneca as Director of Corporate Ventures in June 2023. He holds a PhD and an MBA, and has received teaching and innovation awards; he is also listed on major analyst ranking platforms, although specific securities licenses or FINRA registrations are not publicly detailed.

    Swapnil Malekar's questions to Immuneering (IMRX) leadership

    Swapnil Malekar's questions to Immuneering (IMRX) leadership • Q4 2022

    Question

    Swapnil Malekar from Piper Sandler inquired about the number of patients dosed in the IMM-1-104 trial and the specifics of new data being presented at the upcoming AACR conference, particularly regarding tumor type or mutation status trends.

    Answer

    President and CEO Benjamin Zeskind deferred on providing specific patient numbers, referencing the detailed guidance on data readouts already shared. Regarding the AACR poster, Zeskind and Chief Scientific Officer Brett Hall emphasized its demonstration of "universal-RAS" activity, noting that approximately 85% of the 75 RAS-mutant models tested showed a response, with no single mutation appearing resistant. Hall described the poster as a comprehensive look at their proprietary 3D tumor growth assay platform.

    Ask Fintool Equity Research AI